NKGen Biotech, Inc. presented details on its novel allogeneic blood-derived NK cell therapy ("SNK02") commercial manufacturing and cryopreservation process by Paul Y. Song, MD, Chairman and Chief Executive Officer of NKGen, entitled, "Protecting Patients by removing Need for Lymphodepletion to Better Preserve Immune Function". Dr. Song also provided an update on the Company's initial Phase 1 results using SNK02 to treat patients with advanced refractory solid tumors. Dr. Song's presentation explored the potential benefits of eliminating pre-treatment lymphodepletion in patients undergoing SNK02 therapy, aiming to safeguard immune function and aid in recovery.

Avoiding lymphodepletion before administering cancer treatment can provide many benefits including reduced toxicity, preservation of immune function and potentially enhancing treatment efficacy. The presentation also included a discussion on the results from the Company's Phase 1 SNK02 clinical study in solid tumors previously disclosed in a publication at the 2024 American Society for Clinical Oncology annual meeting. Moreover, unpublished Phase 1 SNK02 data were also presented.

The Phase 1 clinical trial administered SNK02 intravenously ("IV") weekly for a total of 8 weeks with a starting dose of 6 x 109 SNK02 cells in patients with advanced refractory Solid tumors, without lymphodepletion. The primary endpoint was safety based on adverse events, vitals, laboratory tests and physical exams. Tolerability and maximum tolerated dose were also evaluated. Presentation Highlights: In the Phase 1 SNK02 clinical trial, 6 patients, with advanced refractory solid tumor and an average of 4 prior lines of therapy, were enrolled.

The median age was 64 years old (range, 44-71), and 4 were male. The cancer subtypes included 2 colorectal cancers, 1 leiomyosarcoma, 1 angiosarcoma, 1 endometrial ad adocarcinoma, and 1 undifferentiated pleomorphic sarcoma.